These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

723 related items for PubMed ID: 24978857

  • 21. Homologous and heterologous antibody responses to a one-year booster dose of an MF59(®) adjuvanted A/H5N1 pre-pandemic influenza vaccine in pediatric subjects.
    Vesikari T, Forstén A, Borkowski A, Gaitatzis N, Banzhoff A, Clemens R.
    Hum Vaccin Immunother; 2012 Jul; 8(7):921-8. PubMed ID: 22777094
    [Abstract] [Full Text] [Related]

  • 22. Assessment of antigen-specific and cross-reactive antibody responses to an MF59-adjuvanted A/H5N1 prepandemic influenza vaccine in adult and elderly subjects.
    Bihari I, Pánczél G, Kovacs J, Beygo J, Fragapane E.
    Clin Vaccine Immunol; 2012 Dec; 19(12):1943-8. PubMed ID: 23081815
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial.
    Keitel W, Groth N, Lattanzi M, Praus M, Hilbert AK, Borkowski A, Tsai TF.
    Vaccine; 2010 Jan 08; 28(3):840-8. PubMed ID: 19835829
    [Abstract] [Full Text] [Related]

  • 25. Assessment of the safety, tolerability and kinetics of the immune response to A/H1N1v vaccine formulations with and without adjuvant in healthy pediatric subjects from 3 through 17 years of age.
    Arguedas A, Soley C, Abdelnour A, Sales V, Lindert K, Della Cioppa G, Clemens R, Costa Rican H1N1 Vaccine Study Group.
    Hum Vaccin; 2011 Jan 01; 7(1):58-66. PubMed ID: 21285531
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Long-term and cross-reactive immunogenicity of inactivated trivalent influenza vaccine in the elderly: MF59-adjuvanted vaccine versus unadjuvanted vaccine.
    Song JY, Cheong HJ, Noh JY, Seo YB, Choi WS, Cho GJ, Hwang TG, Kim WJ.
    J Med Virol; 2013 Sep 01; 85(9):1591-7. PubMed ID: 23852684
    [Abstract] [Full Text] [Related]

  • 29. Immunogenicity, safety and tolerability of MF59-adjuvanted seasonal influenza vaccine in children with juvenile idiopathic arthritis.
    Dell'Era L, Corona F, Daleno C, Scala A, Principi N, Esposito S.
    Vaccine; 2012 Jan 20; 30(5):936-40. PubMed ID: 22138210
    [Abstract] [Full Text] [Related]

  • 30. In vitro assessment of the allergenicity of novel MF59-adjuvanted pandemic H1N1 influenza vaccine produced in dog kidney cells.
    Bencharitiwong R, Leonard S, Tsai T, Nowak-Węgrzyn A.
    Hum Vaccin Immunother; 2012 Jul 20; 8(7):863-5. PubMed ID: 22777093
    [Abstract] [Full Text] [Related]

  • 31. Trivalent and quadrivalent MF59(®)-adjuvanted influenza vaccine in young children: a dose- and schedule-finding study.
    Della Cioppa G, Vesikari T, Sokal E, Lindert K, Nicolay U.
    Vaccine; 2011 Nov 03; 29(47):8696-704. PubMed ID: 21906647
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Randomized Controlled Trial of Adjuvanted Versus Nonadjuvanted Influenza Vaccine in Kidney Transplant Recipients.
    Kumar D, Campbell P, Hoschler K, Hidalgo L, Al-Dabbagh M, Wilson L, Humar A.
    Transplantation; 2016 Mar 03; 100(3):662-9. PubMed ID: 26335915
    [Abstract] [Full Text] [Related]

  • 36. Response to 2009 pandemic and seasonal influenza vaccines co-administered to HIV-infected and HIV-uninfected former drug users living in a rehabilitation community in Italy.
    Pariani E, Boschini A, Amendola A, Poletti R, Anselmi G, Begnini M, Ranghiero A, Cecconi G, Zanetti AR.
    Vaccine; 2011 Nov 15; 29(49):9209-13. PubMed ID: 21974995
    [Abstract] [Full Text] [Related]

  • 37. Safety and Immunogenicity of Cell Culture-Derived A/H3N2 Variant Influenza Vaccines: A Phase I Randomized, Observer-Blind, Dose-Ranging Study.
    Johnson C, Hohenboken M, Poling T, Jaehnig P, Kanesa-Thasan N.
    J Infect Dis; 2015 Jul 01; 212(1):72-80. PubMed ID: 25538277
    [Abstract] [Full Text] [Related]

  • 38. Immunogenicity of avian influenza A/Anhui/01/2005(H5N1) vaccine with MF59 adjuvant: a randomized clinical trial.
    Belshe RB, Frey SE, Graham IL, Anderson EL, Jackson LA, Spearman P, Edupuganti S, Mulligan MJ, Rouphael N, Winokur P, Dolor RJ, Woods CW, Walter EB, Chen WH, Turley C, Edwards KM, Creech CB, Hill H, Bellamy AR, National Institute of Allergy and Infectious Diseases–Funded Vaccine and Treatment Evaluation Units.
    JAMA; 2014 Oct 08; 312(14):1420-8. PubMed ID: 25291578
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Combined, concurrent, and sequential administration of seasonal influenza and MF59-adjuvanted A/H5N1 vaccines: a phase II randomized, controlled trial of immunogenicity and safety in healthy adults.
    Lopez P, Caicedo Y, Sierra A, Tilman S, Banzhoff A, Clemens R.
    J Infect Dis; 2011 Jun 15; 203(12):1719-28. PubMed ID: 21606530
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 37.